Arizona State Retirement System Has $840,000 Stake in Amedisys, Inc. (NASDAQ:AMED)

Arizona State Retirement System grew its holdings in shares of Amedisys, Inc. (NASDAQ:AMED) by 2.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,145 shares of the health services provider’s stock after purchasing an additional 177 shares during the quarter. Arizona State Retirement System’s holdings in Amedisys were worth $840,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently bought and sold shares of AMED. Charles Schwab Investment Management Inc. grew its holdings in Amedisys by 2.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 312,032 shares of the health services provider’s stock valued at $29,662,000 after purchasing an additional 8,422 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in Amedisys by 74.0% during the fourth quarter. BNP Paribas Financial Markets now owns 5,692 shares of the health services provider’s stock worth $541,000 after buying an additional 2,421 shares in the last quarter. Norges Bank bought a new stake in Amedisys in the 4th quarter valued at $34,032,000. Hilltop Holdings Inc. acquired a new position in Amedisys in the fourth quarter worth about $2,001,000. Finally, Allianz Asset Management GmbH boosted its holdings in Amedisys by 146.0% during the fourth quarter. Allianz Asset Management GmbH now owns 39,855 shares of the health services provider’s stock valued at $3,789,000 after purchasing an additional 23,655 shares in the last quarter. 94.36% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have issued reports on AMED shares. Cantor Fitzgerald reissued a “neutral” rating and set a $101.00 price objective on shares of Amedisys in a report on Thursday, July 25th. William Blair downgraded shares of Amedisys from an “outperform” rating to a “market perform” rating in a research note on Monday, July 1st. Finally, Deutsche Bank Aktiengesellschaft downgraded Amedisys from a “buy” rating to a “hold” rating and set a $101.00 price objective on the stock. in a report on Monday, July 29th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $100.67.

Amedisys Trading Up 0.1 %

Shares of NASDAQ AMED opened at $96.91 on Friday. The company’s 50 day simple moving average is $97.75 and its 200 day simple moving average is $94.69. The firm has a market capitalization of $3.17 billion, a P/E ratio of -151.42, a P/E/G ratio of 1.89 and a beta of 0.78. Amedisys, Inc. has a fifty-two week low of $89.55 and a fifty-two week high of $98.95. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.16 and a quick ratio of 1.16.

Amedisys (NASDAQ:AMED) last posted its earnings results on Wednesday, July 24th. The health services provider reported $1.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.22 by $0.10. Amedisys had a return on equity of 12.39% and a net margin of 4.02%. The company had revenue of $591.19 million during the quarter, compared to analyst estimates of $579.34 million. On average, analysts predict that Amedisys, Inc. will post 4.66 EPS for the current year.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.